Loading clinical trials...
Loading clinical trials...
A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)
Conditions
Interventions
Allogeneic Bone Marrow Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation
+9 more
Locations
1
United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
January 1, 2012
Primary Completion Date
October 29, 2017
Completion Date
November 22, 2019
Last Updated
December 10, 2019
NCT04239157
NCT05636514
NCT06859424
NCT06994676
NCT06523556
NCT06543381
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions